
    
      QUANARIE study is an interventional, prospective, multicenter trial involving 9 french
      oncological centers. Patients diagnosed with mRCC initiating TKI anti-VEGF treatment
      (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research
      and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before
      each visit with the physician. Questionnaires completion will be done by patients on tablets
      and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at
      hospital before consultation or at home via secured portal. Physician will immediately have
      access to a visual summary of HRQOL evaluation.
    
  